Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic and prognostic insights from the analysis of cancer mutational signatures.

Trends in genetics : TIG - 1 Feb 2022

Brady Samuel W, Gout Alexander M, Zhang Jinghui

Abstract excerpt

The somatic mutations in each cancer genome are caused by multiple mutational processes, each of which leaves a characteristic imprint (or 'signature'), potentially caused by specific etiologies or exposures. Deconvolution of these signatures offers a glimpse into the evolutionary history of individual tumors. Recent work has shown that mutational signatures may also yield therapeutic and prognostic insights,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Poly(ADP-ribose) Polymerases

Share to Prognosis

Share to Renal cell carcinoma treatment

Source

Open in PubMed Open full text

Identifiers

PMID: 34483003
DOI: 10.1016/j.tig.2021.08.007
PMCID: PMC8752466

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic and prognostic insights from the analysis of cancer mutational signatures.PMID 34483003Read ↗

Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.Semantic proximity Read ↗

Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.Semantic proximity Read ↗

The mutational footprints of cancer therapiesSemantic proximity Read ↗

Predictive biomarkers for cancer therapy with PARP inhibitors.Semantic proximity Read ↗

Mutational signatures are markers of drug sensitivity of cancer cells.Semantic proximity Read ↗

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?Semantic proximity Read ↗

Mutational signatures are markers of drug sensitivity of cancer cellsSemantic proximity Read ↗

PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant CancersSemantic proximity Read ↗

Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A ReviewSemantic proximity Read ↗

Cancer therapy shapes the fitness landscape of clonal hematopoiesis.Semantic proximity Read ↗

Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency.Semantic proximity Read ↗

The mutational footprints of cancer therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.